Hologic (HOLX) | Financial Analysis & Statements
Hologic Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2025Income Metrics
Revenue
1.0B
Gross Profit
583.5M
55.59%
Operating Income
252.9M
24.09%
Net Income
187.2M
17.84%
EPS (Diluted)
$0.83
Balance Sheet Metrics
Total Assets
9.2B
Total Liabilities
3.9B
Shareholders Equity
5.2B
Debt to Equity
0.75
Cash Flow Metrics
Operating Cash Flow
269.1M
Free Cash Flow
194.8M
Revenue & Profitability Trend
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2025
Hologic Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4.1B | 4.0B | 4.0B | 4.9B | 5.6B |
| Cost of Goods Sold | 2.0B | 1.8B | 2.0B | 1.9B | 1.8B |
| Gross Profit | 2.1B | 2.2B | 2.1B | 3.0B | 3.8B |
| Gross Margin % | 51.6% | 55.3% | 51.4% | 61.6% | 67.4% |
| Operating Expenses | |||||
| Research & Development | 248.2M | 272.8M | 294.3M | 283.4M | 276.3M |
| Selling, General & Administrative | 1.1B | 994.8M | 987.6M | 1.0B | 994.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B |
| Operating Income | 785.4M | 931.0M | 761.5M | 1.6B | 2.5B |
| Operating Margin % | 19.2% | 23.1% | 18.9% | 33.5% | 44.1% |
| Non-Operating Items | |||||
| Interest Income | 74.4M | 108.7M | 120.5M | 12.9M | 1.4M |
| Interest Expense | 117.1M | 122.1M | 111.1M | 95.1M | 93.6M |
| Other Non-Operating Income | -61.5M | -52.5M | -94.8M | 39.6M | -29.6M |
| Pre-tax Income | 681.2M | 865.1M | 676.1M | 1.6B | 2.4B |
| Income Tax | 115.5M | 75.6M | 220.1M | 286.2M | 491.4M |
| Effective Tax Rate % | 17.0% | 8.7% | 32.6% | 18.0% | 20.8% |
| Net Income | 565.7M | 789.5M | 456.0M | 1.3B | 1.9B |
| Net Margin % | 13.8% | 19.6% | 11.3% | 26.8% | 33.2% |
| Key Metrics | |||||
| EBITDA | 1.2B | 1.3B | 1.2B | 2.1B | 2.9B |
| EPS (Basic) | $2.50 | $3.35 | $1.85 | $5.18 | $7.28 |
| EPS (Diluted) | $2.49 | $3.32 | $1.83 | $5.13 | $7.21 |
| Basic Shares Outstanding | 226156000 | 235723000 | 246772000 | 251527000 | 257046000 |
| Diluted Shares Outstanding | 226156000 | 235723000 | 246772000 | 251527000 | 257046000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Hologic Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 2.0B | 2.2B | 2.7B | 2.3B | 1.2B |
| Short-term Investments | 243.2M | 173.4M | 0 | - | - |
| Accounts Receivable | 600.8M | 600.4M | 625.6M | 617.6M | 942.7M |
| Inventory | 679.4M | 679.8M | 617.6M | 623.7M | 501.2M |
| Other Current Assets | 152.0M | 156.2M | 175.3M | 232.2M | 528.8M |
| Total Current Assets | 3.7B | 3.8B | 4.2B | 3.9B | 3.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.1B | 1.0B | 959.0M | 957.7M | 1.0B |
| Goodwill | 7.9B | 7.7B | 7.5B | 7.8B | 8.2B |
| Intangible Assets | 589.1M | 844.6M | 888.6M | 1.3B | 1.7B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 306.3M | 193.3M | 133.6M | 86.9M | 88.3M |
| Total Non-Current Assets | 5.3B | 5.3B | 5.0B | 5.2B | 5.8B |
| Total Assets | 9.0B | 9.2B | 9.1B | 9.1B | 8.9B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 193.4M | 203.8M | 175.2M | 197.7M | 215.9M |
| Short-term Debt | 33.4M | 64.8M | 310.5M | 41.4M | 343.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | 8.2M | 175.7M | 168.1M |
| Total Current Liabilities | 977.2M | 1.0B | 1.2B | 937.7M | 1.3B |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.6B | 2.6B | 2.6B | 2.9B | 2.8B |
| Deferred Tax Liabilities | 373.8M | 371.2M | 294.5M | 342.4M | 460.5M |
| Other Non-Current Liabilities | 10.2M | 10.6M | 13.2M | 25.3M | 16.2M |
| Total Non-Current Liabilities | 3.0B | 3.0B | 2.9B | 3.3B | 3.4B |
| Total Liabilities | 4.0B | 4.0B | 4.1B | 4.2B | 4.7B |
| Equity | |||||
| Common Stock | 3.0M | 3.0M | 3.0M | 3.0M | 3.0M |
| Retained Earnings | 3.4B | 2.8B | 2.1B | 1.6B | 298.3M |
| Treasury Stock | 4.6B | 3.9B | 3.0B | 2.5B | 2.0B |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 5.0B | 5.1B | 5.0B | 4.9B | 4.2B |
| Key Metrics | |||||
| Total Debt | 2.6B | 2.7B | 2.9B | 2.9B | 3.1B |
| Working Capital | 2.7B | 2.8B | 3.0B | 2.9B | 1.8B |
Balance Sheet Composition
Hologic Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 565.7M | 789.5M | 456.0M | 1.3B | 1.9B |
| Depreciation & Amortization | 299.8M | 309.0M | 323.4M | 430.1M | 406.9M |
| Stock-Based Compensation | 84.3M | 82.3M | 79.6M | 66.7M | 65.0M |
| Working Capital Changes | -20.1M | 25.1M | -15.0M | 109.0M | 61.2M |
| Operating Cash Flow | 831.5M | 1.2B | 748.9M | 1.7B | 2.4B |
| Investing Activities | |||||
| Capital Expenditures | -78.2M | -57.8M | -58.4M | -56.6M | -59.4M |
| Acquisitions | -321.5M | -328.6M | -5.0M | -158.6M | -1.2B |
| Investment Purchases | -181.9M | -310.2M | -10.0M | 0 | - |
| Investment Sales | 176.0M | - | - | - | - |
| Investing Cash Flow | -408.5M | -698.6M | -60.3M | -135.7M | -1.2B |
| Financing Activities | |||||
| Share Repurchases | -752.9M | -835.1M | -474.8M | -542.1M | -409.8M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 1.2B | 0 | 0 | 1.5B | 1.3B |
| Debt Repayment | -1.2B | -291.3M | -19.0M | -1.7B | -1.4B |
| Financing Cash Flow | -816.0M | -1.1B | -526.2M | -1.0B | -831.1M |
| Free Cash Flow | 904.7M | 1.1B | 901.0M | 2.0B | 2.1B |
| Net Change in Cash | -393.0M | -663.6M | 162.4M | 561.0M | 321.1M |
Cash Flow Trend
Hologic Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
31.54
Forward P/E
15.64
Price to Book
3.23
Price to Sales
4.11
PEG Ratio
-3.92
Profitability Ratios
Profit Margin
13.18%
Operating Margin
22.99%
Return on Equity
10.86%
Return on Assets
7.43%
Financial Health
Current Ratio
4.04
Debt to Equity
48.05
Beta
0.70
Per Share Data
EPS (TTM)
$2.41
Book Value per Share
$23.51
Revenue per Share
$18.37
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| HOLX | 17.0B | 31.54 | 3.23 | 10.86% | 13.18% | 48.05 |
| Intuitive Surgical | 170.1B | 54.97 | 8.99 | 16.69% | 28.38% | 0.95 |
| Becton, Dickinson | 56.1B | 25.40 | 1.75 | 6.96% | 8.01% | 77.28 |
| Alcon | 45.8B | 40.84 | 2.07 | 5.23% | 11.28% | 23.63 |
| ResMed | 32.0B | 21.69 | 5.06 | 25.68% | 27.53% | 13.41 |
| West Pharmaceutical | 22.1B | 40.99 | 6.94 | 19.13% | 16.85% | 10.73 |
Financial data is updated regularly. All figures are in the company's reporting currency.






